Corporate News Analysis: ADAR1 Capital’s Recent Purchases of InMed Pharmaceuticals

The acquisition of four additional shares by ADAR1 Capital Management, LLC on October 23, 2026 represents a continuation of the firm’s systematic accumulation strategy in InMed Pharmaceuticals (ticker: INMD). While the transaction size is modest in dollar terms, it is part of a broader buying wave that has elevated ADAR1’s stake from 940,000 to approximately 957,000 shares within a single month. This article examines the strategic significance of the purchases, the clinical and regulatory backdrop of InMed’s ongoing merger with Mentari Therapeutics, and the potential implications for investors and industry stakeholders.

1. Timing and Tactical Rationale

ADAR1’s most recent transaction occurred at $1.32 per share, slightly below the market close of $1.59 on the same day. This price advantage aligns with the firm’s historical pattern of acquiring shares at or near support levels. The accumulation coincided with a 20 % weekly rally, reinforcing the notion that the firm is capitalizing on short‑term momentum to build a position ahead of key corporate events:

  • Merger with Mentari Therapeutics – The announced combination is expected to create a diversified therapeutic portfolio, enhancing both pipeline depth and revenue streams.
  • Contingent Value Rights (CVR) Issuance – The planned CVR distribution on November 5 offers a potential upside contingent on post‑merger milestones, thereby adding value for shareholders who hold the underlying common stock.
  • Return‑of‑Capital Proposal – The forthcoming shareholder vote on a return‑of‑capital plan provides an additional catalyst for price appreciation.

By purchasing shares close to the market price and ahead of these milestones, ADAR1 positions itself to benefit from the anticipated valuation lift without committing a large portion of its capital.

2. Accumulation Strategy and Shareholder Concentration

Over the past 60 days, ADAR1’s average purchase price has ranged from $1.33 to $1.36, comfortably below the 52‑week high of $2.33. The incremental build has maintained a disciplined, step‑wise approach—typically acquiring a few thousand shares per trade—while occasionally scaling up during periods of pronounced momentum, such as the May 2026 spike that saw a 200,000‑share purchase at $1.56.

With the current holding representing roughly 10 % of InMed’s outstanding shares, the firm has increased its influence within the company’s ownership structure. Although this concentration is not yet sufficient to alter control dynamics, it does raise the profile of block trades and could amplify short‑term volatility should a sizable transaction materialize. For the broader shareholder base, the presence of a sophisticated private‑equity investor buying at support levels may be interpreted as a bullish endorsement of the company’s valuation prospects.

3. Clinical and Regulatory Context

InMed’s pipeline features several late‑stage clinical candidates across oncology and rare‑disease indications. The merger with Mentari brings complementary assets, including a portfolio of immuno‑oncology candidates that have shown promise in phase II studies. The integration is expected to streamline regulatory pathways and leverage shared clinical development resources.

The CVR mechanism, tied to the achievement of specific post‑merger performance metrics (e.g., regulatory approvals, sales milestones), provides an additional layer of upside for InMed shareholders. Regulatory scrutiny will focus on the clarity of the CVR terms, the likelihood of triggering events, and the financial impact on shareholder equity. A successful CVR distribution could materially enhance the intrinsic value of common shares, thereby supporting the upward price trend observed in recent weeks.

4. Risk Considerations

  • Execution Risk – The merger and CVR triggers are contingent on regulatory approvals, which carry inherent uncertainty. Delays or adverse decisions could dampen the expected price appreciation.
  • Integration Risk – Combining two pharmaceutical entities poses challenges related to culture, operations, and intellectual property alignment. Missteps could affect the projected synergies.
  • Market Volatility – The current rally is partly driven by speculative interest in the merger announcement. A reversal in sentiment could lead to a rapid price correction, impacting ADAR1’s holding value.

5. Outlook for Investors

ADAR1’s continued purchases suggest confidence in the strategic trajectory of InMed Pharmaceuticals. For healthcare professionals and informed investors, the key takeaways are:

  1. Strategic Value Creation – The merger and CVR plan represent significant upside potential, especially if regulatory milestones are met.
  2. Controlled Accumulation – ADAR1’s disciplined approach reduces the risk of large, disruptive trades while maintaining a foothold in a company poised for growth.
  3. Short‑Term Volatility – The concentration of ownership may lead to price swings, particularly around key corporate events.

Monitoring subsequent ADAR1 transactions will be critical. A sustained buying trend could presage a breakout, while a pause or reversal might signal caution. Ultimately, the combination of clinical pipeline strength, regulatory alignment, and strategic corporate actions positions InMed Pharmaceuticals as a company warranting close observation.